Dong-A ST Co. Ltd.’s DA-1726 is a novel oxyntomodulin analogue and balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist under investigation for the treatment of obesity.

Current treatments for Graves’ hyperthyroidism (GH) and Graves’ orbitopathy (GO) are ineffective. Researchers assessed the preclinical in vitro efficacy of SYD-5115 (Byondis BV), a novel low-molecular-weight thyrotropin receptor (TSH-R) antagonist. The compound comprises an N-acetylated dihydropyrrole pyrimidine core with various substituents, including a difluorinated-spirocyclohexyl ring and a chiral carbamate group on the pyrimidine ring.

Investigators from Foresee Pharmaceuticals Co. Ltd., Medical University of Vienna and Cleveland Clinic recently reported data on the effects of the matrix metalloproteinase-12 (MMP-12) inhibitor FP-020 in a mouse model of cardiac sarcoidosis in which chronic activation of mTORC1 signaling in myeloid cells causes spontaneous cardiac sarcoid-like granulomas.

Primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) are chronic inflammatory liver diseases. It is known that one of the cell signaling molecules overexpressed in the liver during inflammation is IL-18, which is also a marker of hepatocyte injury and liver steatosis.

Larkspur Biosciences Inc. recently published findings uncovering a role for B cells in antitumor immunity, and highlighting TIM-1 as a targetable checkpoint protein central to B-cell antitumor activity.